BC
NTLA icon

Brookfield Corp’s Intellia Therapeutics NTLA Stock Holding History

Brookfield Corp’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-12,831
Closed -$478K – 707
2023
Q1 		$478K Buy
+12,831
New +$503K ﹤0.01% 579

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Brookfield Corp's NTLA Position: Q2 2023 in Review

Brookfield Corp sold out of Intellia Therapeutics (NTLA) in Q2 2023, closing a stake of 12,831 shares — an estimated $478K sold.

Brookfield Corp first reported a position in NTLA in Q1 2023 and held it in 1 quarter. The position peaked at $478K in Q1 2023. 290 funds tracked by Wall St. Rank hold NTLA as of Q2 2023.

  • Brookfield Corp reported no remaining Intellia Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Brookfield Corp sold 12,831 Intellia Therapeutics shares in Q2 2023, an estimated $478K.
  • Brookfield Corp first reported a position in Intellia Therapeutics in Q1 2023 and held it in 1 quarter.
  • Brookfield Corp's Intellia Therapeutics position peaked at $478K in Q1 2023.
  • 290 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2023.

Based on Brookfield Corp's 13F filing for Q2 2023, filed 14 Aug 2023.